NEW YORK, NY--(Marketwire - August 7, 2008) - Delcath Systems, Inc. (NASDAQ: DCTH) today announced that Richard L. Taney, President and CEO of Delcath Systems, Inc., will present at the 28th Annual Canaccord Adams Global Growth Conference on Tuesday, August 12th, 2008 at 10:30 AM EDT. The conference will be held at the Intercontinental Hotel in Boston, Massachusetts from August 12th through 14th, 2008. The Canaccord Adams Global Growth Conference has continuously brought together high-quality institutional investors with some of the best small- to mid-cap companies in the Technology, Life Sciences, Industrial Growth, and Consumer sectors.

Mr. Taney's presentation will be webcast live and available for replay via the following web address:

It will also be archived on Delcath's website at

About Delcath Systems, Inc.

Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company has developed a proprietary, patented system which will improve the efficacy of cancer treatment while reducing the considerable, systemic side-effects of chemotherapy. Delcath's novel drug delivery platform is capable of delivering anti-cancer drugs at very high doses to a specific organ or region of the body while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

Contact Information: Company Contact: Delcath Systems, Inc. Richard Taney (212) 489-2100 Investor Relations Contact: Strategic Growth International, Inc. Richard E. Cooper (212) 838-1444